title: Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study.
abstract: Patients with liver cirrhosis and a superimposed acute injury with progressive hyperbilirubinemia have a high mortality. A prospective, controlled study was performed to test whether hyperbilirubinemia, 30-day survival, and encephalopathy would be improved by extracorporeal albumin dialysis (ECAD). Twenty-four patients were studied; 23 patients had cirrhosis; 1 had a prolonged cholestatic drug reaction and was excluded from per protocol (PP) analysis. Patients had a plasma bilirubin greater than 20 mg/dL and had not responded to prior standard medical therapy (SMT). Patients were randomized to receive SMT with ECAD or without (control). ECAD was performed with an extracorporeal device that dialyzes blood in a hollow fiber dialyzer (MW cutoff < 60 kd) against 15% albumin. Albumin-bound molecules transfer to dialysate albumin that is regenerated continuously by passage through a charcoal and anion exchange column and a conventional dialyzer. ECAD was associated with improved 30-day survival (PP, 11 of 12 ECAD, 6 of 11 controls; log rank P <.05). Plasma bile acids and bilirubin decreased on average by 43% and 29%, respectively, in the ECAD group after 1 week of treatment, but not in the control group. Renal dysfunction and hepatic encephalopathy improved in the ECAD group, but worsened significantly in the control group. ECAD was safe, with adverse events being rare and identical in both groups. In conclusion, ECAD appears to be effective and safe for the short-term treatment of patients with cirrhosis and superimposed acute injury associated with progressive hyperbilirubinemia and may be useful for increasing survival in such patients awaiting liver transplantation.
authors.affiliation: Department of Internal Medicine, University of Essen, Germany.
authors.forename: Uwe
authors.initials: U
authors.lastname: Heemann
authors.forename: Ulrich
authors.initials: U
authors.lastname: Treichel
authors.forename: Jan
authors.initials: J
authors.lastname: Loock
authors.forename: Thomas
authors.initials: T
authors.lastname: Philipp
authors.forename: Guido
authors.initials: G
authors.lastname: Gerken
authors.forename: Massimo
authors.initials: M
authors.lastname: Malago
authors.forename: Sebastian
authors.initials: S
authors.lastname: Klammt
authors.forename: Matthias
authors.initials: M
authors.lastname: Loehr
authors.forename: Stephan
authors.initials: S
authors.lastname: Liebe
authors.forename: Steffen
authors.initials: S
authors.lastname: Mitzner
authors.forename: Reinhardt
authors.initials: R
authors.lastname: Schmidt
authors.forename: Jan
authors.initials: J
authors.lastname: Stange
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D006932:Hyperbilirubinemia / Q000150:complications / Q000401:mortality / Q000628:therapy*; D008103:Liver Cirrhosis / Q000150:complications / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011446:Prospective Studies; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods*; D012709:Serum Albumin / Q000378:metabolism*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D012709:Serum Albumin